

# De Novo Biosynthesis of Glycosylated Carotenoids in Escherichia Coli

**Xixian Chen**

Singapore Institute of Food and Biotechnology Innovation (SIFBI)

**Xiaohui Lim**

Singapore Institute of Food and Biotechnology Innovation (SIFBI)

**Aurelie Bouin**

Singapore Institute of Food and Biotechnology Innovation (SIFBI); TBI, Université de Toulouse

**Thomas Lautier**

Singapore Institute of Food and Biotechnology Innovation (SIFBI); TBI, Université de Toulouse

**Congqiang Zhang** (✉ [zcqsimon@outlook.com](mailto:zcqsimon@outlook.com))

Singapore Institute of Food and Biotechnology Innovation (SIFBI) <https://orcid.org/0000-0003-1070-8806>

---

## Research

**Keywords:** Carotenoids, metabolic engineering, synthetic biology, glycosylation, glucosyltransferase, zeaxanthin, astaxanthin, UPD-glucose.

**Posted Date:** May 6th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-480662/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Bioresources and Bioprocessing on July 29th, 2021. See the published version at <https://doi.org/10.1186/s40643-021-00415-0>.

1 De novo biosynthesis of glycosylated  
2 carotenoids in *Escherichia coli*

3  
4 Xixian Chen<sup>1</sup>, Xiao Hui Lim<sup>1</sup>, Aurelie Bouin<sup>1,2</sup>, Thomas Lautier<sup>1,2</sup>, Congqiang  
5 Zhang<sup>1\*</sup>

6  
7 <sup>1</sup>*Singapore Institute of Food and Biotechnology Innovation (SIFBI), Agency for Science,*  
8 *Technology and Research (A\*STAR), Singapore.*

9 <sup>2</sup>*TBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France*

10 \* To whom correspondence should be addressed.

11 Congqiang Zhang: SIFBI, A\*STAR, Proteos level 4, Singapore 138673;

12 Email: [zcqsimon@outlook.com](mailto:zcqsimon@outlook.com); [congqiang\\_zhang@sifbi.a-star.edu.sg](mailto:congqiang_zhang@sifbi.a-star.edu.sg)

13

14 **Abstract**

15 Carotenoids have wide applications in food, feed, pharmaceutical and cosmetic industries.  
16 The fast-growing market demands highlight the importance of developing new routes for  
17 carotenoid biosynthesis. Meanwhile, a complementary need is to improve low  
18 bioavailability because of the hydrophobicity of carotenoids. One solution is glycosylation,

19 which can substantially increase the water solubility of carotenoids, and enhance the  
20 bioavailability, photostability and biological activities as food supplements and medicines.  
21 Here, we report metabolic engineering efforts to produce glycosylated carotenoids in  
22 *Escherichia coli*. By fine tuning the 14 gene pathway, our strain produced up to 47.2 mg/L  
23 (~11670 ppm) of zeaxanthin glucosides, ~78% of the total carotenoids produced. In  
24 another construct with 15-gene pathway, the strain produced a mixture of carotenoid  
25 glucosides including astaxanthin and adonixanthin glucosides with a total yield of 8.1 mg/L  
26 (1774 ppm). Our work demonstrated a proof-of-concept study for the microbial  
27 biosynthesis of glycosylated carotenoids. (145 words)

28 **Keyword:** Carotenoids, metabolic engineering, synthetic biology, glycosylation,  
29 glucosyltransferase, zeaxanthin, astaxanthin, UPD-glucose.

## 30 **Introduction**

31 Carotenoids (>1,100) are natural pigments widely distributed in plants, animals, algae and  
32 microbes (Yabuzaki 2017; Zhang 2018). The structures of carotenoids typically consist of  
33 an electron-rich polyene chain with nine or more conjugated double bonds. This unique  
34 feature contributes primarily to their photo-protection and light-harvesting property,  
35 antioxidant activities to quench free radicals and singlet oxygen, and vivid colors  
36 (Sandmann 2019). Carotenoids function as photosynthesis and photoprotection agents in  
37 photosynthetic organisms (e.g., plants and algae) and protect non-photosynthetic  
38 organisms (e.g., bacteria, archaea and fungi) from photooxidative damages (Hashimoto  
39 et al. 2016). Carotenoids also serve as structural molecules by integrating in lipid  
40 membranes, hence, modulating membrane fluidity (Richter et al. 2015). Because of these  
41 properties, especially for the pigment and health benefits, carotenoids have various  
42 applications in food, feed, nutraceutical and pharmaceutical industries, and the industrial  
43 demand is growing rapidly. For example, the global market of astaxanthin is projected to  
44 reach \$2.57 billion worldwide by 2025 (Zhang et al. 2020).

45 However, most natural carotenoids are lipophilic and hardly soluble in water. The  
46 hydrophobicity of carotenoids limits their application in medicine and food where enhanced  
47 water dispensability is required to facilitate their effective uptake or use (Dembitsky 2005;  
48 Hada et al. 2012). Therefore, several attempts, mainly chemical approaches (e.g.,  
49 converting carotenoids to salts of carotenoid esters, or forming carotenoid-cyclodextrin  
50 complex), have been made to increase the carotenoid hydrophilicity (Hada et al. 2012).  
51 Alternatively, glycosylation is an excellent natural way to increase carotenoid solubility. In  
52 nature, a large number of hydrophobic natural products (e.g., lipids and terpenes) are

53 glycosylated into more water-soluble products by glycosyltransferases (Elshahawi et al.  
54 2015). In fact, water-soluble carotenoids, although rare, are present in nature, such as  
55 crocins (or glycosyl polyene esters) in saffron (Dembitsky 2005). In addition, several other  
56 glycosylated carotenoids are uncovered in various microbes, such as zeaxanthin  
57 glucoside (Misawa et al. 1990), astaxanthin glucoside (Yokoyama et al. 1998),  
58 adonixanthin- $\beta$ -D-glucoside (Yokoyama et al. 1995), sioxanthin (Richter et al. 2015) and  
59 a C50 decaprenoxanthin diglucoside (Krubasik et al. 2001).

60 Natural metabolites are typically produced meaningfully with biological functions for host  
61 living organisms. Primary metabolites are synthesized to support their growth and  
62 development. Secondary metabolites typically increase the competitiveness of the  
63 organism within its environment. Likewise, glycosylated carotenoids should have  
64 meaningful functions for their hosts. It is reported that glycosylated carotenoids play  
65 important roles in maintaining cell wall structure and their localization stabilizes the  
66 thylakoid membrane in cyanobacteria where the glycosyl moiety serves as a binding motif  
67 that enables the proper folding and stacking of the thylakoid membrane (Mohamed et al.  
68 2005). The first bacterial gene that encodes the enzyme to catalyze carotenoid  
69 glycosylation was identified in *Pantoea ananatis* (previously as *Erwinia uredovora*)  
70 (Misawa et al. 1990) and it was reported that glycosylation can alter carotenoid deposition  
71 in plants (Wurtzel 2019). As a phytopathogen, this might contribute to the virulence of *P.*  
72 *ananatis* with host plant cells. Moreover, carotenoid glucosides contribute to the heat  
73 resistance of the *Thermus* species, and hence, are also named thermoxanthins (Hada et  
74 al. 2012). As for commercial applications, apart from improved water solubility (e.g., the  
75 solubility of zeaxanthin, zeaxanthin mono- and diglucosides are 12.6, 100 and 800 ppm in  
76 water, respectively (Hundle et al. 1992)), glycosylation of carotenoids also leads to

77 structural diversity and several other benefits, such as increased bioavailability and  
78 efficacy as food supplements and medicines, and improved photostability (Polyakov et al.  
79 2009) and biological activities (e.g., antioxidant activity) of carotenoids (Matsushita et al.  
80 2000). It is proposed that the increase in antioxidant activities is not from their intrinsic  
81 ability of additional glucosides to scavenge free radicals, but arises from the enhanced  
82 affinity with singlet oxygen, the location and orientation in cells (Choi et al. 2013;  
83 Matsushita et al. 2000).

84 Carotenoids are glycosylated by glycosyltransferases (GTs), which is a large enzyme  
85 family. GTs typically catalyze a hydroxyl or carboxyl group of lipophilic substrates as the  
86 substituent moiety for glycosylation. For carotenoid glycosylation, the hydroxyl group is  
87 the commonest substituent moiety, and the carotenoid GTs belong to GT family 1 or GT1.  
88 Uridine diphosphate- $\alpha$ -D-glucose (UDP-glucose) is the most abundant sugar donor to  
89 carotenoid glycosylation. In addition, other sugars such as L-rhamnose, L-fucose, D-  
90 xylose and L-quinovose can also be recruited especially in cyanobacteria (Choi et al.  
91 2013).

92 To date, only a couple of studies have demonstrated the biosynthesis of carotenoid  
93 glucosides in *Escherichia coli* and in several natural microbial producers (Choi et al. 2013;  
94 Misawa et al. 1990; Yokoyama et al. 1995; Yokoyama et al. 1998). However, these studies  
95 only produced detectable amount of carotenoid glucosides and were far from the minimal  
96 requirement for industrial applications. Here, using the zeaxanthin glucosyltransferase  
97 (ZGT, the gene *crtX*, UniProt ID D4GFK6) from *P. ananatis*, we have constructed a 14-  
98 and 15-gene pathway in *E. coli* to synthesize various carotenoid glucosides, such as  
99 zeaxanthin D-glucoside (yellow) and astaxanthin D-glucoside (red). The carotenoid yields

100 have been improved by rational metabolic engineering approaches and bioprocess  
101 optimization.

102

## 103 **Results**

### 104 **The pathway design for glycosylated carotenoids**

105 The metabolic pathway for glycosylated carotenoids was designed on top of our previous  
106 optimized astaxanthin strain (Zhang et al. 2018). Briefly, the mevalonate pathway genes  
107 were cloned into the modules 1 (AHT, the genes *atoB*, *hmgB* and truncated *hmgR*) and 2  
108 (MPPI, the genes *mevk*, *pmk*, *pmd* and *idi*) and the lycopene pathway genes (*crtEBI* and  
109 *ispA*) were located in module 3 (EBIA). The last module (module 4, YZX or YZWX)  
110 consists of the genes to produce zeaxanthin glucosides (*crtY*, *crtZ*, and *crtX*) or to produce  
111 astaxanthin glucosides (*crtY*, *crtZ*, *crtW*, and *crtX*) (Figure 1). All the modules were  
112 controlled by T7 and its variants (e.g., TM1, TM2 and TM3) and induced by isopropyl  $\beta$ -d-  
113 1-thiogalactopyranoside (IPTG) (Zhang et al. 2015). This modular arrangement provides  
114 the flexibility to balance the global pathways (14-15 genes) and to fine tune the local  
115 pathways (e.g., module 4). In addition, as the module 4 controls the cyclization (*crtY*),  
116 hydroxylation (*crtZ*), ketolation (*crtW*), and glycosylation (*crtX*) of carotenoids, it is  
117 relatively simple to switch from one carotenoid (e.g., using *crtYZ* to produce zeaxanthin)  
118 to another one (e.g., using *crtYZWX* to astaxanthin glucoside) without modifying the  
119 upstream pathways genes.

## 120 **The production of glycosylated zeaxanthin**

121 Firstly, we used the modules 1-3 and the module 4 (YZX) to demonstrate the capability to  
122 produce zeaxanthin glucoside. We developed a LC-TOF-MS method to detect the  
123 carotenoids and their glucosides (summary in Table 1). In the constructed strain with *crtX*,  
124 we managed to detect five carotenoids: lycopene,  $\beta$ -carotene, zeaxanthin, zeaxanthin- $\beta$ -  
125 D-glucoside and zeaxanthin- $\beta$ -D-diglucoside, whereas the control strain without *crtX* did  
126 not produce either glycosylated zeaxanthin (Figure 2A). The intermediate  $\beta$ -cryptoxanthin  
127 was not detected in either strain. The LC chromatograms and mass spectra for zeaxanthin  
128 (m/z 568.428, Table 1), zeaxanthin- $\beta$ -D-glucoside (m/z 730.481) and zeaxanthin- $\beta$ -D-  
129 diglucoside (m/z 892.534) were shown in Figures 2A and B. In addition, we also purified  
130 some zeaxanthin glucosides from the strain with *crtX* and obtained a yellow aqueous  
131 solution (~30 mg/L). In contrast, zeaxanthin barely dissolves in water leading to a  
132 transparent water solution (Figure 2C).

## 133 **Optimization of glycosylation of zeaxanthin**

134 In our first design strain X0, the glycosylation of zeaxanthin was incomplete: ~26.8 % of  
135 monoglycosylated and 59.0% of diglycosylated (here the percentage was calculated by  
136 normalizing to the total yield of zeaxanthin and its two glucosides) and 14.2% of  
137 zeaxanthin remained unglycosylated (Figure 3A and B). We hypothesized that  
138 glycosylation of zeaxanthin could be limited by insufficient activity of ZGT. To test it, we  
139 re-designed another four ribosomal binding sites (RBSs) of *crtX* which have relatively  
140 higher translational efficiencies than the initial RBS in strain X0 (Figure 3C). Indeed, we  
141 observed that using stronger RBS for ZGT (*crtX*) led to higher glycosylation of zeaxanthin  
142 (Figure 3A and D). Strain X1 had the strongest RBS and produced the highest amount of

143 zeaxanthin- $\beta$ -D-diglucoside (~3139 ppm and ~87.4% of total zeaxanthin and its  
144 glucosides). We attempted to correlate RBS strengths to zeaxanthin- $\beta$ -D-diglucoside  
145 production. Zeaxanthin- $\beta$ -D-glucoside produced appears to reach a saturated percentage  
146 when RBS relative strength was higher than 0.3 (Figure 3D).

147 Next, we evaluated the effect of different carbon sources on the biosynthesis of zeaxanthin  
148 glucosides. As an abundant and inexpensive carbon source, we chose glucose and  
149 hypothesized that glucose might be advantageous to supply additional UDP-glucose,  
150 which is the key cofactor for carotenoid glycosylation. UDP-glucose can be produced from  
151 glucose with three enzymes: *glk*: glucokinase, *pgm*: phosphoglucomutase, *galU*: UDP-  
152 glucose pyrophosphorylase (Mao et al. 2006; Shrestha et al. 2019). In addition, we also  
153 chose glycerol as it is inexpensive and was reported to favour carotenoid production  
154 (Zhang et al. 2013). For X1 strain, the glucose supplementation (10 g/L) led to higher  
155 production of zeaxanthin glucosides (~3650 ppm) than the supplementation of 10 g/L of  
156 glycerol or the mixture of glucose (5 g/L) and glycerol (5 g/L) (Figure 4A). Subsequently,  
157 we increased the amount of supplemented glucose from 10 to 20 g/L, the yield of  
158 zeaxanthin diglucoside was further increased from ~3400 (or 15.1 mg/L) to ~4690 ppm (or  
159 25.3 mg/L). At the same time, OD<sub>600</sub> was also increased from 10.8 to 13.1 (Figure 4B). Of  
160 the total carotenoids produced including lycopene and  $\beta$ -carotene, zeaxanthin glucosides  
161 reached about 64% in X1 strain.

162 In addition, we also observed that lycopene was accumulated as the main intermediate  
163 carotenoid for all the strains and conditions in Figures 3A and 4A. We hypothesized that  
164 the accumulation of lycopene could arise from the insufficient activity of lycopene cyclase  
165 (or *crtY*, Figure 1). Indeed, the introduction of extra copies of *crtY* (“+*crtY*” strain)

166 significantly boosted zeaxanthin diglucoside yield from 3400 to 7150 ppm (or 23.1 mg/L)  
167 and zeaxanthin glucoside yield from 350 to 4520 ppm (14.6 mg/L) in the medium  
168 supplemented with 10 g/L glucose (Figure 4B). Furthermore, for the “+crtY” strain, the  
169 titres of zeaxanthin diglucoside and glucoside were further increased to 31.0 and 16.3  
170 mg/L, respectively, as the supplemented glucose was increased from 10 to 20 g/L (Figure  
171 4B). Lastly, the yields of zeaxanthin glucosides of “+crtY” strain were about 78% of that of  
172 total carotenoids produced.

### 173 **Distribution of carotenoids in *E. coli* cells**

174 While studying the zeaxanthin glucoside strain, we observed that some cells of zeaxanthin  
175 production strain were longer than others in microscopes (Figure 5A). In comparison, there  
176 were no elongated cells for zeaxanthin glucoside production strain. We wondered if the  
177 cell shape difference was attributed to the higher hydrophilicity of zeaxanthin glucosides  
178 so that most zeaxanthin glucosides may be distributed in cytosol. To test the hypothesis,  
179 we analysed the distribution of carotenoids between cytosol and membrane.  
180 Unexpectedly, it was found that all the four carotenoids (lycopene,  $\beta$ -carotene, zeaxanthin  
181 and zeaxanthin glucosides) were predominantly localized in membrane (Figure 5B). Less  
182 than 2% of them were present in cytosol. In addition, less zeaxanthin glucosides (0.08%)  
183 was distributed in cytosol as compared to zeaxanthin (1.13%). Our data supported the  
184 notion that zeaxanthin and its glucosides might have higher affinity with membrane than  
185 cytosol. Structurally, the glucoside and carotene of carotenoid glucosides resemble the  
186 hydrophilic head and the hydrophobic tail of phospholipid bilayers, respectively; also, the  
187 dimension of bilayer inner membrane ( $37.5 \pm 0.5 \text{ \AA}$ ) (Mitra et al. 2004) is close to that of  
188 zeaxanthin diglucoside ( $\sim 30 \text{ \AA}$ ) (Figure 5B). Carotenoid glucosides are reported to be

189 clustered in rigid patches and such local rigidity can protect the membrane integrity under  
190 internal or external stress (e.g., oxidative and extreme temperature) (Mohamed et al.  
191 2005). This might attribute to cell shape difference between zeaxanthin and zeaxanthin-  
192 glucoside producing cells, and further study is warranted to explore the mechanism.

### 193 **The production of glycosylated astaxanthin**

194 After demonstrating our design was working for zeaxanthin glycosylation, we further tested  
195 the other design with module YZWX to produce astaxanthin glucosides. With the addition  
196 of the gene *crtX* in one of our best astaxanthin producer strains (Ast strain, Figure 6A and  
197 B) (Zhang et al. 2018), we tested the astaxanthin glycosylation capability (the resulting  
198 strain was named GA01). Overall, seven carotenoid glucosides are detected in GA01:  
199 zeaxanthin- $\beta$ -D-glucoside, adonirubin- $\beta$ -D-glucoside (m/z 742.444), adonixanthin- $\beta$ -D-  
200 glucoside (m/z 744.460), astaxanthin- $\beta$ -D-glucoside (m/z 758.439), zeaxanthin- $\beta$ -D-  
201 diglucoside, adonixanthin- $\beta$ -D-diglucoside (m/z 906.513) and astaxanthin- $\beta$ -D-diglucoside  
202 (m/z 920.492, Figure 6A and B, Table 1, mass spectra in Figures 6C and Supplementary  
203 Figure S1, and LC chromatograms in Supplementary Figure S2 and S3). Among them,  
204 astaxanthin- $\beta$ -D-glucoside was the main glycosylated product with a yield of 4.51 mg/L  
205 (968 ppm), about 68% of total carotenoid glucosides. In addition, about 4.82 mg/L  
206 astaxanthin (1035 ppm) was not glycosylated and larger amount of  $\beta$ -carotene (16.0 mg/L,  
207 3426 ppm) remained in GA01 strain. Furthermore, we observed that the introduction of  
208 *crtX* resulted in the total carotenoid yields in GA01 strain dropped by 54%, as compared  
209 to its parental Ast strain (Figure 6A), which might be due to the overall perturbation to the  
210 mevalonate and carotenoid pathway carbon fluxes or feedback regulations.

## 211 **Optimization of glycosylation of astaxanthin**

212 Moreover, the higher IPTG concentration reduced the total yield of glycosylated  
213 carotenoids from 6.61 to 3.60 mg/L (1418 to 799 ppm) and non-glycosylated (or aglycones)  
214 carotenoids from 24.8 to 15.7 mg/L (5320 to 3485 ppm, Figure 6A), possibly because  
215 IPTG perturbed the whole biosynthetic pathway where all the genes were controlled by  
216 T7 promoter variants and/or it promoted a competition between CrtZ and CrtW with  
217 intermediate accumulation (Figure 1). It has been observed that the translational efficiency  
218 of the  $\beta$ -carotene hydroxylase (*crtZ*) is more crucial than that of  $\beta$ -carotene ketolase (*crtW*)  
219 on astaxanthin production (Zhang et al. 2018). Therefore, we used nine different ribosomal  
220 binding sites (RBSs, Supplementary Table S1) covering from 1% to 100% of translational  
221 efficiencies (the strains were named G01-09, translational efficiencies were normalized to  
222 that of strain GA01, the strongest among them) to optimize the production of glycosylated  
223 carotenoids, especially glycosylated astaxanthin.

224 Essentially, GA01-09 were strains with the same design except for the different RBSs of  
225 *crtZ* (Supplementary Table S1). Indeed, the RBS had marked effects on the carotenoid  
226 production and distribution (Figure 6A and B, Supplementary Figure S4). For GA08 and  
227 GA09, the total carotenoid yields were very low, below 10 mg/L (<2000 ppm), and the  
228 carotenoid glucosides were also very low, below 0.4 mg/L (<100 ppm). GA01 and GA02  
229 had the highest glycosylation efficiency (~21%, Figure 6A), but with relatively lower total  
230 carotenoid yields as compared to GA03, GA04 and GA05. Surprisingly, GA03, with a  
231 relatively weaker RBS (Supplementary Table S1), had the highest yield of total  
232 carotenoids (11623 ppm) and total glycosylated carotenoids (1774 ppm). Similar to GA01,  
233 strains GA02-07 had lower yields of carotenoids (including glycosylated carotenoids)

234 when IPTG concentrations increased from 0.03 to 0.1 mM. In contrast, strains GA08-09  
235 had higher yields when IPTG dosage increased, likely due to the relatively weaker RBSs  
236 of *crtZ*.

237 RBS engineering of *crtZ* has enhanced the production of glycosylated and total  
238 carotenoids by 25% and 72%, respectively, as compared to that of GA01. However, unlike  
239 the obvious positive effect of RBS of *crtX* on zeaxanthin glucosides (Figure 3D), the data  
240 in Supplementary Figure S4 indicated the lack of correlation between the RBS strength of  
241 *crtZ* and carotenoid production. The lack of correlation was not surprising as the top two  
242 producers, GA03 and GA05, had relative weaker RBSs.

243

## 244 **Discussion**

245 Here, we successfully engineered *E. coli* to produce carotenoid glucosides in high  
246 amounts. Particularly, our zeaxanthin-glucoside strain produced 11670 ppm of two  
247 zeaxanthin glucosides (~7150 ppm of zeaxanthin diglucose, ~4520 ppm of zeaxanthin  
248 glucoside) in 2-day batch fermentation (Figure 4B). In contrast, the astaxanthin-glucoside  
249 strains (GA01-09) produced lower amount of total carotenoid glucosides (1774 ppm) but  
250 with high diversity where 7 carotenoid glucosides were detected. To the best of our  
251 knowledge, our study is the first to produce these carotenoid glucosides (up to 7 varieties)  
252 in recombinant microbes.

253 Our results here supported that ZGT, belonging to the GT1 family, was able to glycosylate  
254 various other carotenoids (e.g., adonirubin, adonixanthin), in addition to the reported  
255 zeaxanthin and astaxanthin (Hundle et al. 1992; Yokoyama et al. 1998). Furthermore, if

256 xanthophylls have two hydroxyl groups (e.g., astaxanthin), di-glycosylated products can  
257 also be produced by ZGT. Considering the complexity of the carotenoid pathway and the  
258 promiscuity of ZGT, the product diversity was not surprising as the glycosylation reaction  
259 competed with other reactions (hydroxylation or ketolation, Figure 1). The presence of  
260 bulky glycoside moiety may prevent the glycosylated intermediates (e.g., zeaxanthin and  
261 adonixanthin) from further ketolation to astaxanthin glucosides by the  $\beta$ -carotene ketolase  
262 (*crtW*), hence, all the carotenoid glucosides became the end products (Figure 1).

263 To improve the glycosylation of zeaxanthin, we have employed RBS engineering (strong  
264 RBS for ZGT), media optimization and supplementation of additional lycopene cyclase  
265 (*crtY*). All the strategies were very effective, collectively, they enhanced the yields of the  
266 two zeaxanthin glucosides from 1640 ppm to 11670 ppm, or by 7.1 fold. However, it was  
267 not straightforward for astaxanthin glycosylation. A possible reason is that the ZGT from  
268 *P. ananatis* might have relatively lower activity for astaxanthin than zeaxanthin. The keto  
269 group may also stabilize the hydroxyl group or introduces steric hinderance and thus  
270 reduces accessibility by ZGT. Also, the competitions for carotenoid intermediates by  
271 ketolases (*CrtW*), hydroxylases (*CrtZ*) and ZGT increase the ramification of the metabolic  
272 pathway. To further improve the production of astaxanthin glucosides, four strategies can  
273 be employed in the future: (1) to explore the natural diversity of ZGTs for more suitable  
274 enzymes; (2) to balance the expression of Module 4 (Figure 1); (3) to further manipulate  
275 the intracellular UDP-glucose supply; 4) to implement a dynamic regulation to trigger  
276 glycosylation after the formation of astaxanthin. A search in UniProt database resulted in  
277 254 zeaxanthin GT homologues from 69 microbial genera, particularly in *Pseudomonas*,  
278 *Pantoea* and *Massilia*, which have 88, 22, 12 of homologues identified, respectively.  
279 Experimental screening may lead to identifying some candidates with higher activities

280 and/or specificities for astaxanthin. Furthermore, the data in Figures 3 and 6 indicated that  
281 the perturbation of *crtZ* and *crtX* expression had strong effects on both yields of total  
282 carotenoids and glycosylated carotenoids. The parental strain (Ast) had produced  
283 astaxanthin as the main product, however, all the GA01-09 strains had  $\beta$ -carotene  
284 accumulated intracellularly (Figure 6B). This indicated that previously balanced pathway  
285 was perturbed by the introduction of ZGT. A solution is to refine the module 4 by  
286 RBS/promoter engineering or organisation shuffling of operon genes to minimizing the  
287 accumulation of intermediates (e.g., lycopene and  $\beta$ -carotene, Figure 6B). Lastly, unlike  
288 zeaxanthin glycosylation strain with high glycosylation efficiency (>90%), the astaxanthin  
289 glycosylation was relatively low (40-50%) indicating they might be still limited by the  
290 accessible intracellular UDP-glucose, whose supply can be enhanced by overexpressing  
291 UDP-glucose biosynthetic pathway genes (e.g., *glk*: glucokinase, *pgm*:  
292 phosphoglucomutase, *galU*: UDP-glucose pyrophosphorylase) and by utilizing other types  
293 of UDP-sugars with glycosyltransferases. The strategy has been successfully applied to  
294 increase the production of flavonoids such as anthocyanins (Shrestha et al. 2019; Zha et  
295 al. 2020) and is worth exploring on carotenoid glycosylation.

## 296 **Conclusion**

297 We have developed microbial strains to overproduce various carotenoid glucosides. The  
298 metabolic engineering and bioprocess strategies are proven to be effective and have  
299 synergic effects in improving the yields of carotenoid glucosides by balancing the  
300 metabolic pathways and supplying carbon precursors and important cofactors. Our study  
301 here demonstrated a proof-of-concept study for microbial production of glycosylated

302 carotenoids and might inspire the production for other high-value metabolites, especially  
303 other glycosylated metabolites.

304

## 305 **Methods**

### 306 **Strain and plasmid construction**

307 *E. coli* BI21-Gold DE3 strain (Stratagene) was used in this study. The plasmids p15A-  
308 *spec-hmgS-atoB-hmgR* (L2-8), p15A-*spec-crtY-hmgS-atoB-hmgR* (L2-8) p15A-*cam-*  
309 *mevK-pmk-pmd-idi* (L2-5), p15A-*kan-crtEBI-ispA* were designed as previously described  
310 (Zhang et al. 2018). The zeaxanthin GT gene (*crtX*) from *Pantoea ananatis* was inserted  
311 in the operon of the plasmids p15A-amp-crtYZ (L2-9) and p15A-amp-crtYZW (L2-9)  
312 (Zhang et al. 2018) to obtain p15A-amp-crtYZX and p15A-amp-crtYZWX, respectively.

### 313 **Construction of RBS library**

314 CrtZ RBS library was created using the degenerate primer and followed by screening and  
315 sequencing validations, using the same cloning method as previously described (Zhang  
316 et al. 2018). RBS strengths or translation efficiencies were predicted by RBS Calculator,  
317 version 2.0 (Farasat et al. 2014).

### 318 **Tube culture of the *E. coli* strains**

319 The medium used was TB medium (20 g/L tryptone, 24 g/L yeast extract, 17 mM KH<sub>2</sub>PO<sub>4</sub>,  
320 and 72 mM K<sub>2</sub>HPO<sub>4</sub>) and 2XPY medium (20 g/L peptone, 10 g/L yeast extract and 10 g/L  
321 NaCl), supplemented with 10 g/L glycerol or 10-20 g/L glucose or their mixture (5 g/L  
322 glucose + 5 g/L glycerol), 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

323 (HEPES), as previously described (Zhang et al. 2018). For strain optimization, the cells  
324 were grown in 1 mL of TB or 2XPY medium in 14 ml BD Falcon™ tube at 28 °C/250 rpm  
325 for 2-3 days. The cells were also grown in 50 mL culture in shaking flasks for validation of  
326 the carotenoid production. The cells were initially grown at 37 °C/250 rpm until OD<sub>600</sub>  
327 reached ~0.8, induced by 0.03-0.1 mM IPTG, and were subsequently grown at 28 °C for  
328 2 days. The antibiotics (34 µg/ml chloramphenicol, 50 µg/ml kanamycin, 50 µg/ml  
329 spectinomycin and 100 µg/ml ampicillin) were supplemented in the culture to maintain the  
330 four plasmids.

### 331 **Microscope imaging of *E. coli* cells**

332 For microscopy assay, *E. coli* cells were directly sampled from cell cultures. Cell amount  
333 was normalized by OD<sub>600</sub> and directly observed at 1000 magnification using a Leica  
334 DM6000B microscope. Neither centrifuge nor washing steps were introduced to avoid  
335 perturbation of the cell morphologies.

### 336 **Extraction and quantification of carotenoids**

337 Total intracellular carotenoids were extracted from cellular pellets according to the acetone  
338 extraction method (Zhang et al. 2018). Briefly, 10–50 µL bacterial culture (depending on  
339 the content of carotenoids in the cells) was collected and centrifuged. Cell pellets were  
340 washed with PBS and were resuspended in 20 µL of water, followed by addition of 180 µL  
341 of acetone and vigorous homogenization for 20 min. After 10 minutes of centrifugation  
342 at 14,000 *g*, the supernatant was collected and filtered using a PTFE, 0.45µm filter.

343 The separation of carotenoids from cytosol and cell membranes was done by differential  
344 centrifugation. Briefly, cell pellets collected from 1mL of culture were resuspended in 1ml

345 lysis buffer (50mM Tris HCl of pH 7.5, 200mM NaCl, 1 mg/ml lysozyme of pH 8) before  
346 3x30 sec sonication at 4 °C (75% amplitude). The cell lysate was subsequently  
347 centrifugated for 10 minutes at 14,000 *g*. The supernatant containing the cytosol fraction  
348 of carotenoids and the pellet debris containing the membrane fraction were extracted  
349 separately with by 1mL of extraction buffer (hexane: acetone: ethanol at 2:1:1 volumetric  
350 ratio).

### 351 **Quantification of carotenoids**

352 All the carotenoids were analysed by Agilent 1290 Infinity II UHPLC System coupled with  
353 Diode Array Detector (DAD) detector and 6230B TOF MS platform. The LC/MS method  
354 was similar to previously described (Zhang et al. 2018). Briefly, 1 µL of purified carotenoids  
355 in acetone was injected into the Agilent ZORBAX RRHD Eclipse Plus C18 2.1X50 mm,  
356 1.8 µm. Separation was carried out at a flow rate of 0.5 mL/min. The mobile phase and  
357 gradient used were as follows. The analysis started from 10% water (0.1% formic acid),  
358 10% methanol (0.1% formic acid) and 80% acetonitrile (0.1% formic acid) and this  
359 condition was maintained for 2 min, followed by the increase in methanol from 10% to 90%  
360 and the decrease in water from 10% to 0 and acetonitrile from 80% to 10% within 0.1 min.  
361 The condition (90% methanol and 10% acetonitrile) was continued for 7 min. The whole  
362 analysis finished at 10 min. Mass spectrometry was operated to scan 100-1100 *m/z* in  
363 ESI-positive mode with 4000 V capillary voltage. Nebulizer gas was supplied at 35 psig  
364 and dry gas flow was 10 L/min. Gas temperature was set at 325 °C. Sheath gas was set  
365 at 350 °C and 12 L/min. Retention time was determined with chemical standards or  
366 calculated based on chromatography profile for those carotenoids without standards.

367 Carotenoid concentrations were calculated based on the peak area of each compound  
368 extracted by their corresponding m/z value (Table 1) or UV absorbance at 450 nm  
369 (Supplementary Figure S2). Standard curves were generated for the five chemical  
370 standards with extracted-ion chromatogram (EIC) peak areas (Supplementary Figure S3):  
371 lycopene,  $\beta$ -carotene, astaxanthin, canthaxanthin (Sigma-Aldrich, St. Luis, MO, USA), and  
372 zeaxanthin (Santa Cruz Biotechnology, Dallas, TX, USA). For those carotenoids without  
373 standards, the concentration was calculated based on the relative peak area to its close  
374 compartment. For example, the concentrations of zeaxanthin glucoside and zeaxanthin  
375 diglucoside were calculated based on that of zeaxanthin; the concentrations of astaxanthin  
376 glucosides, adonixanthin and its diglucosides were calculated based on that of astaxanthin.  
377 Carotenoid contents were calculated by normalizing the titres with dry cell weight ( $\mu$ g  
378 carotenoids per gram DCW, or ppm) (Zhang et al. 2018).

### 379 **Data availability**

380 All data supporting the findings of this study are available in the article, Supplementary  
381 Information, or upon request from the corresponding author.

### 382 **Abbreviations**

383 GT: glycosyltransferase; UDP-glucose: Uridine diphosphate- $\alpha$ -D-glucose; ZGT,  
384 zeaxanthin glucosyltransferase; IPTG, isopropyl  $\beta$ -d-1-thiogalactopyranoside; RBS:  
385 ribosomal binding site.

386

387 **Declarations**

388 **Ethics approval and consent to participate**

389 Not applicable.

390 **Consent for publication**

391 The publication of the paper has been agreed by the authors.

392 **Competing interests**

393 The authors declare that they have no potential conflicts of interest.

394 **Funding**

395 This research was supported by AME Young Individual Research Grant (YIRG)  
396 A2084c0064 (Dr Congqiang Zhang) and A1984c0040 (Dr Xixian Chen), Agency for  
397 Science, Technology and Research (A\*STAR), Singapore.

398 **Acknowledgements**

399 We acknowledge Prof Heng-Phon Too, National University of Singapore, Dr Nicholas  
400 David Lindley, Dr Ee Lui Ang and Dr Hazel Khoo, Singapore Institute of Food and  
401 Biotechnology Innovation, for the support and insightful suggestions of the project.

402 **Author contributions**

403 C.Z. conceived the project, analyzed the results, and wrote the manuscript. X.C., X.L., and  
404 C.Z designed and did the experiments of strain engineering. T.L. and A.B. designed and  
405 did the microscope imaging of *E. coli* and quantification of carotenoid distributed in

406 membrane and cytosol. All authors contributed to the discussion and approved the final  
407 manuscript.

408

## 409 **Reference**

410 Choi SK, Osawa A, Maoka T, et al. (2013) 3-beta-Glucosyl-3'-beta-quinovosyl zeaxanthin,  
411 a novel carotenoid glycoside synthesized by *Escherichia coli* cells expressing the *Pantoea*  
412 *ananatis* carotenoid biosynthesis gene cluster. *Appl Microbiol Biotechnol* 97(19):8479-86.  
413 doi:10.1007/s00253-013-5101-9

414 Dembitsky VM (2005) Astonishing diversity of natural surfactants: 3. Carotenoid  
415 glycosides and isoprenoid glycolipids. *Lipids* 40(6):535-57. doi:10.1007/s11745-005-  
416 1415-z

417 Elshahawi SI, Shaaban KA, Kharel MK, Thorson JS (2015) A comprehensive review of  
418 glycosylated bacterial natural products. *Chem Soc Rev* 44(21):7591-697.  
419 doi:10.1039/c4cs00426d

420 Farasat I, Kushwaha M, Collens J, et al. (2014) Efficient search, mapping, and  
421 optimization of multi-protein genetic systems in diverse bacteria. *Mol Syst Biol* 10(6):731-  
422 731. doi:10.15252/msb.20134955

423 Hada M, Nagy V, Deli J, Agocs A (2012) Hydrophilic carotenoids: recent progress.  
424 *Molecules* 17(5):5003-12. doi:10.3390/molecules17055003

425 Hashimoto H, Uragami C, Cogdell RJ (2016) Carotenoids and Photosynthesis. In: Stange  
426 C (ed) Carotenoids in Nature: Biosynthesis, Regulation and Function. Springer  
427 International Publishing, Cham, pp 111-139

428 Hundle BS, O'Brien DA, Alberti M, et al. (1992) Functional expression of zeaxanthin  
429 glucosyltransferase from *Erwinia herbicola* and a proposed uridine diphosphate binding  
430 site. *Proc Natl Acad Sci U S A* 89(19):9321-5. doi:10.1073/pnas.89.19.9321

431 Krubasik P, Takaichi S, Maoka T, et al. (2001) Detailed biosynthetic pathway to  
432 decaprenoxanthin diglucoside in *Corynebacterium glutamicum* and identification of novel  
433 intermediates. *Arch Microbiol* 176(3):217-223. doi:10.1007/s002030100315

434 Mao Z, Shin HD, Chen RR (2006) Engineering the *E. coli* UDP-glucose synthesis pathway  
435 for oligosaccharide synthesis. *Biotechnol Prog* 22(2):369-74. doi:10.1021/bp0503181

436 Matsushita Y, Suzuki R, Nara E, et al. (2000) Antioxidant activity of polar carotenoids  
437 including astaxanthin- $\beta$ -glucoside from marine bacterium on PC liposomes. *Fisheries*  
438 *Science* 66(5):980-985. doi:10.1046/j.1444-2906.2000.00155.x

439 Misawa N, Nakagawa M, Kobayashi K, et al. (1990) Elucidation of the *Erwinia uredovora*  
440 carotenoid biosynthetic pathway by functional analysis of gene products expressed in  
441 *Escherichia coli*. *J Bacteriol* 172(12):6704-12. doi:10.1128/jb.172.12.6704-6712.1990

442 Mitra K, Ubarretxena-Belandia I, Taguchi T, et al. (2004) Modulation of the bilayer  
443 thickness of exocytic pathway membranes by membrane proteins rather than cholesterol.  
444 *Proc Natl Acad Sci U S A* 101(12):4083-8. doi:10.1073/pnas.0307332101

445 Mohamed HE, van de Meene AM, Roberson RW, Vermaas WF (2005) Myxoxanthophyll  
446 is required for normal cell wall structure and thylakoid organization in the cyanobacterium  
447 *Synechocystis* sp. strain PCC 6803. *J Bacteriol* 187(20):6883-92.  
448 doi:10.1128/JB.187.20.6883-6892.2005

449 Polyakov NE, Leshina TV, Meteleva ES, et al. (2009) Water Soluble Complexes of  
450 Carotenoids with Arabinogalactan. *The Journal of Physical Chemistry B* 113(1):275-282.  
451 doi:10.1021/jp805531q

452 Richter TK, Hughes CC, Moore BS (2015) Sioxanthin, a novel glycosylated carotenoid,  
453 reveals an unusual subclustered biosynthetic pathway. *Environ Microbiol* 17(6):2158-71.  
454 doi:10.1111/1462-2920.12669

455 Sandmann G (2019) Antioxidant Protection from UV- and Light-Stress Related to  
456 Carotenoid Structures. *Antioxidants (Basel)* 8(7):219. doi:10.3390/antiox8070219

457 Shrestha B, Pandey RP, Darsandhari S, et al. (2019) Combinatorial approach for  
458 improved cyanidin 3-O-glucoside production in *Escherichia coli*. *Microb Cell Fact* 18(1):7.  
459 doi:10.1186/s12934-019-1056-6

460 Wurtzel ET (2019) Changing Form and Function through Carotenoids and Synthetic  
461 Biology. *Plant Physiol* 179(3):830-843. doi:10.1104/pp.18.01122

462 Yabuzaki J (2017) Carotenoids Database: structures, chemical fingerprints and  
463 distribution among organisms. Database: *The Journal of Biological Databases and*  
464 *Curation* 2017:bax004. doi:10.1093/database/bax004

465 Yokoyama A, Adachi K, Shizuri Y (1995) New Carotenoid Glucosides, Astaxanthin  
466 Glucoside and Adonixanthin Glucoside, Isolated from the Astaxanthin-Producing Marine  
467 Bacterium, *Agrobacterium aurantiacum*. *J Nat Prod* 58(12):1929-1933.  
468 doi:10.1021/np50126a022

469 Yokoyama A, Shizuri Y, Misawa N (1998) Production of new carotenoids, astaxanthin  
470 glucosides, by *Escherichia coli* transformants carrying carotenoid biosynthesis genes.  
471 *Tetrahedron Lett* 39(22):3709-3712. doi:10.1016/s0040-4039(98)00542-5

472 Zha J, Wu X, Koffas MA (2020) Making brilliant colors by microorganisms. *Curr Opin*  
473 *Biotechnol* 61:135-141. doi:10.1016/j.copbio.2019.12.020

474 Zhang C (2018) Biosynthesis of Carotenoids and Apocarotenoids by Microorganisms and  
475 Their Industrial Potential. *Progress in Carotenoid Research*:85.

476 Zhang C, Chen X, Too H-P (2020) Microbial astaxanthin biosynthesis: recent  
477 achievements, challenges, and commercialization outlook. *Appl Microbiol Biotechnol*  
478 104(13):5725-5737. doi:10.1007/s00253-020-10648-2















479 Zhang C, Chen X, Zou R, et al. (2013) Combining genotype improvement and statistical  
480 media optimization for isoprenoid production in *E. coli*. *PLoS ONE* 8(10):e75164.  
481 doi:10.1371/journal.pone.0075164






482 Zhang C, Seow VY, Chen X, Too HP (2018) Multidimensional heuristic process for high-  
483 yield production of astaxanthin and fragrance molecules in *Escherichia coli*. *Nat Commun*  
484 9(1):1858. doi:10.1038/s41467-018-04211-x

485 Zhang C, Zou R, Chen X, et al. (2015) Experimental design-aided systematic pathway  
486 optimization of glucose uptake and deoxyxylulose phosphate pathway for improved  
487 amorphadiene production. *Appl Microbiol Biotechnol* 99(9):3825-37. doi:10.1007/s00253-  
488 015-6463-y

489 **Tables**

490 Table 1. Carotenoid information.

NO.	Compound	Chemical structures	RT (min)	Chemical Formula	Monoisotopic Mass (m/z)
1	$\beta$ -carotene		8.84	C <sub>40</sub> H <sub>56</sub>	536.438
2	lycopene		7.37	C <sub>40</sub> H <sub>56</sub>	536.438
3	echinenone		5.07	C <sub>40</sub> H <sub>54</sub> O	550.417
4	$\beta$ -cryptoxanthin		4.53	C <sub>40</sub> H <sub>56</sub> O	552.433
5	canthaxanthin		3.38	C <sub>40</sub> H <sub>52</sub> O <sub>2</sub>	564.397
6	3'-hydroxyechinenone		n.d. <sup>1</sup>	C <sub>40</sub> H <sub>54</sub> O <sub>2</sub>	566.412
7	zeaxanthin		2.11	C <sub>40</sub> H <sub>56</sub> O <sub>2</sub>	568.428
8	adonirubin		1.91	C <sub>40</sub> H <sub>52</sub> O <sub>3</sub>	580.392
9	adonixanthin		1.35	C <sub>40</sub> H <sub>54</sub> O <sub>3</sub>	582.407
10	astaxanthin		0.98	C <sub>40</sub> H <sub>52</sub> O <sub>4</sub>	596.387
11	$\beta$ -cryptoxanthin- $\beta$ -D-glucoside		n.d.	C <sub>46</sub> H <sub>66</sub> O <sub>6</sub>	714.486
12	3'-hydroxyechinenone- $\beta$ -D-glucoside		n.d.	C <sub>46</sub> H <sub>64</sub> O <sub>7</sub>	728.465
13	zeaxanthin- $\beta$ -D-glucoside		0.78	C <sub>46</sub> H <sub>66</sub> O <sub>7</sub>	730.481
14	adonirubin- $\beta$ -D-glucoside		0.81	C <sub>46</sub> H <sub>62</sub> O <sub>8</sub>	742.444

15	adonixanthin-β-D-glucoside		0.51	C <sub>46</sub> H <sub>64</sub> O <sub>8</sub>	744.460
16	astaxanthin-β-D-glucoside		0.43	C <sub>46</sub> H <sub>62</sub> O <sub>9</sub>	758.439
17	zeaxanthin-β-D-digluconide		0.37	C <sub>52</sub> H <sub>76</sub> O <sub>12</sub>	892.534
18	adonixanthin-β-D-digluconide		0.31	C <sub>52</sub> H <sub>74</sub> O <sub>13</sub>	906.513
19	astaxanthin-β-D-digluconide		0.30	C <sub>52</sub> H <sub>72</sub> O <sub>14</sub>	920.492

491 <sup>1</sup> Here, n.d. stands for not detected.

492

493 **Figure legend**

494 **Fig. 1. Biosynthetic pathway of carotenoid glucosides**

495 The biosynthetic pathway: module 1 AHT, including *atoB*, *hmgS* and *thmgR*; module 2  
496 MPPI, including *mevk*, *pmk*, *pmd* and *idi*; module 3 EBIA, including *crtEBI* and *ispA* (Zhang  
497 et al. 2018); and module 4 YZX or YZWX, including *crtYZX* or *crtYZWX*. Dashed arrow  
498 indicates multiple enzymatic steps. The glycosylation of all carotenoids required UDP-  
499 glucose (UDP-glc), here we only used zeaxanthin glucosides as representatives. The  
500 genes expressed encode the following enzymes: *crtY*, lycopene beta-cyclase; *crtW*,  $\beta$ -  
501 carotene ketolase; *crtZ*,  $\beta$ -carotene hydroxylase; *crtX*, zeaxanthin glucosyltransferase  
502 (ZGT). Thicker and thinner arrows represent the higher and lower carbon flux, respectively;  
503 grey arrows represent that the metabolites (e.g.,  $\beta$ -cryptoxanthin- $\beta$ -D-glucoside and 3'-  
504 hydroxyechinenone- $\beta$ -D-glucoside) were not detected in our strains.

505 **Fig. 2. Production of zeaxanthin glucosides**

506 (A) LC/MS chromatograms of zeaxanthin strains with and without the expression of *crtX*.  
507 (B) Mass spectra of zeaxanthin and its glucosides. (C) The water solutions of zeaxanthin  
508 and zeaxanthin glucosides.

509 **Fig. 3. Tuning the translation of zeaxanthin glucosyltransferase**

510 (A) Carotenoid contents of zeaxanthin glucoside strains. (B)  $OD_{600}$  of different strains.  
511 Error bars, mean  $\pm$  s.d., n = 3. (C) Different RBSs used for *crtX* and their relative strengths.  
512 (D) Correlation between the glycosylation efficiency of zeaxanthin and the RBS strength  
513 of *crtX*. The glycosylation efficiency is defined as the percentage of zeaxanthin diglucoside  
514 yield to the total yield of zeaxanthin and its two glucosides.

515 **Fig. 4. The effects of carbon sources on the production of zeaxanthin**  
516 **glucosides**

517 (A) Carotenoid contents and OD<sub>600</sub> of strain X1 by comparison of different carbon sources:  
518 10 g/L glucose, 10g/L glycerol and their mixture, 5 g/L glucose + 5 g/L glycerol (glc+gly).  
519 (B) Carotenoid contents and OD<sub>600</sub> of strains X1 and “+crtY” by optimizing the  
520 concentrations of glucose and introduction of additional copies of *crtY*. Error bars, mean  
521 ± s.d., n = 2.

522 **Fig. 5. Structural similarity between membrane and carotenoid**  
523 **diglucosides and its biological benefits.**



524 (A) Comparison between zeaxanthin and zeaxanthin glucosides strains. (B) Carotenoid  
525 distribution between cytosol and membrane. (C) Structural similarity between  
526 phospholipid bilayers and zeaxanthin diglucoside and their dimensions.

527 **Fig. 6. Production of astaxanthin glucosides and other carotenoids**

528 (A) The content sums of glycosylated and unglycosylated carotenoids in different strains.  
529 (B) Carotenoid contents produced in different strains. Blue: 0.03 mM IPTG; orange: 0.1  
530 mM IPTG. ‘Ast’ strain is the parental astaxanthin strain without expressing *crtX*. ‘GA01’ is  
531 the control strain with the highest RBS strength of *crtZ*. (C) Mass spectra of astaxanthin  
532 and its glucosides.

533


Figures  
Fig. 1



- 1, X=H<sub>2</sub>, Y=H<sub>2</sub>, R=H<sub>2</sub>, R<sub>1</sub>=H<sub>2</sub>
- 2, X=H<sub>2</sub>, Y=H<sub>2</sub>, R=OH, R<sub>1</sub>=H<sub>2</sub>
- 3, X=O, Y=H<sub>2</sub>, R=H<sub>2</sub>, R<sub>1</sub>=H<sub>2</sub>
- 4, X=O, Y=H<sub>2</sub>, R=H<sub>2</sub>, R<sub>1</sub>=OH
- 5, X=H<sub>2</sub>, Y=H<sub>2</sub>, R=OH, R<sub>1</sub>=OH
- 6, X=O, Y=O, R=H<sub>2</sub>, R<sub>1</sub>=H<sub>2</sub>
- 7, X=H<sub>2</sub>, Y=O, R=OH, R<sub>1</sub>=OH
- 8, X=O, Y=O, R=OH, R<sub>1</sub>=H<sub>2</sub>

- 9, X=O, Y=O, R=OH, R<sub>1</sub>=OH
- 10, X=H<sub>2</sub>, Y=H<sub>2</sub>, R=OGlc, R<sub>1</sub>=OH
- 11, X=H<sub>2</sub>, Y=H<sub>2</sub>, R=OGlc, R<sub>1</sub>=OGlc
- 12, X=H<sub>2</sub>, Y=O, R=OGlc, R<sub>1</sub>=OH
- 13, X=H<sub>2</sub>, Y=O, R=OGlc, R<sub>1</sub>=OGlc
- 14, X=O, Y=O, R=OGlc, R<sub>1</sub>=OH
- 15, X=O, Y=O, R=OGlc, R<sub>1</sub>=OGlc
- 16, X=O, Y=O, R=OGlc, R<sub>1</sub>=H<sub>2</sub>

**Fig. 2**



**Fig. 3**




Fig. 4








Fig. 5



**Fig. 6**




# Figures



- |  |  |
|--|--|
| 1, X=H <sub>2</sub> , Y=H <sub>2</sub> , R=H <sub>2</sub> , R <sub>1</sub> =H <sub>2</sub> | 9, X=O, Y=O, R=OH, R <sub>1</sub> =OH                                  |
| 2, X=H <sub>2</sub> , Y=H <sub>2</sub> , R=OH, R <sub>1</sub> =H <sub>2</sub>              | 10, X=H <sub>2</sub> , Y=H <sub>2</sub> , R=OGlc, R <sub>1</sub> =OH   |
| 3, X=O, Y=H <sub>2</sub> , R=H <sub>2</sub> , R <sub>1</sub> =H <sub>2</sub>               | 11, X=H <sub>2</sub> , Y=H <sub>2</sub> , R=OGlc, R <sub>1</sub> =OGlc |
| 4, X=O, Y=H <sub>2</sub> , R=H <sub>2</sub> , R <sub>1</sub> =OH                           | 12, X=H <sub>2</sub> , Y=O, R=OGlc, R <sub>1</sub> =OH                 |
| 5, X=H <sub>2</sub> , Y=H <sub>2</sub> , R=OH, R <sub>1</sub> =OH                          | 13, X=H <sub>2</sub> , Y=O, R=OGlc, R <sub>1</sub> =OGlc               |
| 6, X=O, Y=O, R=H <sub>2</sub> , R <sub>1</sub> =H <sub>2</sub>                             | 14, X=O, Y=O, R=OGlc, R <sub>1</sub> =OH                               |
| 7, X=H <sub>2</sub> , Y=O, R=OH, R <sub>1</sub> =OH  | 15, X=O, Y=O, R=OGlc, R <sub>1</sub> =OGlc                             |
| 8, X=O, Y=O, R=OH, R <sub>1</sub> =H <sub>2</sub>  | 16, X=O, Y=O, R=OGlc, R <sub>1</sub> =H <sub>2</sub>                   |


**Figure 1**

Biosynthetic pathway of carotenoid glucosides The biosynthetic pathway: module 1 AHT, including *atoB*, *hmgS* and *thmGR*; module 2 MPPI, including *mevK*, *pmk*, *pmd* and *idi*; module 3 EBIA, including *crtEBI* and *ispA* (Zhang et al. 2018); and module 4 YZX or YZWX, including *crtYZX* or *crtYZWX*. Dashed arrow indicates multiple enzymatic steps. The glycosylation of all carotenoids required UDP glucose (UDP-glc), here we only used zeaxanthin glucosides as representatives. The genes expressed encode the following enzymes: *crtY*, lycopene beta-cyclase; *crtW*, β-carotene ketolase; *crtZ*, β-carotene hydroxylase; *crtX*, zeaxanthin glucosyltransferase (ZGT). Thicker and thinner arrows represent the higher and lower carbon flux, respectively; grey arrows represent that the metabolites (e.g., β-cryptoxanthin-β-D-glucoside and 3'-hydroxyechinenone-β-D-glucoside) were not detected in our strains.




**Figure 2**

Production of zeaxanthin glucosides (A) LC/MS chromatograms of zeaxanthin strains with and without the expression of *crtX*. (B) Mass spectra of zeaxanthin and its glucosides. (C) The water solutions of zeaxanthin and zeaxanthin glucosides.




**Figure 3**

(A) Carotenoid contents of zeaxanthin glucoside strains. (B) OD<sub>600</sub> of different strains. Error bars, mean  $\pm$  s.d., n = 3. (C) Different RBSs used for *crtX* and their relative strengths. (D) Correlation between the glycosylation efficiency of zeaxanthin and the RBS strength of *crtX*. The glycosylation efficiency is defined as the percentage of zeaxanthin diglycoside yield to the total yield of zeaxanthin and its two glucosides.




**Figure 4**

The effects of carbon sources on the 515 production of zeaxanthin glucosides (A) Carotenoid contents and OD<sub>600</sub> of strain X1 by comparison of different carbon sources: 10 g/L glucose, 10g/L glycerol and their mixture, 5 g/L glucose + 5 g/L glycerol (glc+gly). (B) Carotenoid contents and OD<sub>600</sub> of strains X1 and “+crtY” by optimizing the concentrations of glucose and introduction of additional copies of crtY. Error bars, mean ± s.d., n = 2.



**Figure 5**

Structural similarity between membrane and carotenoid diglucosides and its biological benefits. (A) Comparison between zeaxanthin and zeaxanthin glucosides strains. (B) Carotenoid distribution between cytosol and membrane. (C) Structural similarity between phospholipid bilayers and zeaxanthin diglucoside and their dimensions.



**Figure 6**

Production of astaxanthin glucosides and other carotenoids (A) The content sums of glycosylated and unglycosylated carotenoids in different strains. (B) Carotenoid contents produced in different strains. Blue: 0.03 mM IPTG; orange: 0.1 mM IPTG. 'Ast' strain is the parental astaxanthin strain without expressing *crtX*. 'GA01' is the control strain with the highest RBS strength of *crtZ*. (C) Mass spectra of astaxanthin and its glucosides.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Glycosilatedcarotenoidsmanuscripts supplementaryv5.pdf](#)
- [Graphicalabstract.jpg](#)